UC Davis Health researchers have developed a new drug that could offer bladder cancer patients a safer and more effective treatment, potentially reducing the need for chemotherapy or bladder removal surgery.
The therapy, called PLZ4-coated paclitaxel-loaded micelles (PPM), is now in a first-in-human clinical trial and has shown promising early results for patients with non-muscle invasive bladder cancer, according to UC Davis Health.
PPM was developed by Dr. Kit S. Lam, a distinguished professor in the Division of Hematology and Oncology at UC Davis School of Medicine, and Dr. Chong-xian Pan, a former UC Davis professor of medicine and urology.
The treatment uses tiny nanoparticles called micelles, which encapsulate the chemotherapy drug paclitaxel. These micelles are designed to deliver the drug directly into bladder tumors while minimizing exposure to healthy tissues, potentially reducing the severe side effects commonly associated with chemotherapy.
One early patient, a 74-year-old man who had exhausted other treatment options, showed no signs of bladder cancer just six weeks after starting PPM therapy. Clinicians reported that he experienced only mild side effects and was able to resume normal daily activities.
“This early response shows the potential for PPM to control tumors more effectively than conventional intravesical chemotherapy,” said the UC Davis research team.
The development of PPM is the result of collaboration between UC Davis clinician-scientists and materials engineers, aiming to solve the long-standing challenge of delivering high doses of chemotherapy directly to bladder tumors without harming the rest of the body. While paclitaxel is effective, its toxicity has limited its use in bladder cancer. Encapsulation in micelles may allow higher, safer doses.
Bladder cancer is one of the most common cancers in the U.S., with non-muscle invasive cases accounting for most new diagnoses. Current treatment often involves tumor removal followed by chemotherapy or immunotherapy instilled directly into the bladder. Despite these measures, many patients experience recurring tumors, and some eventually require bladder removal.
The UC Davis team believes that a treatment that better penetrates tumors while sparing healthy tissue could significantly improve patient outcomes and quality of life.
PPM also offers practical advantages: it can be delivered directly into the bladder using standard procedures, making integration into existing clinical practices straightforward.
Researchers are continuing to study how long the micelles stay in the bladder, whether they maintain consistent drug levels over time, and whether they reduce tumor recurrence. The clinical trial will expand to enroll more patients to evaluate dosing, safety, and long-term effectiveness, with a particular focus on patients at high risk for tumor progression.
If ongoing trials confirm these early findings, PPM could become an alternative to radical bladder removal for some patients. Funding for the research comes from UC Davis and the U.S. Department of Veterans Affairs.
Related topic：
